Emerging Therapies And Licensing Will Expand Royalty Opportunities

Published
08 Aug 24
Updated
14 Aug 25
AnalystConsensusTarget's Fair Value
US$43.27
17.0% undervalued intrinsic discount
14 Aug
US$35.92
Loading
1Y
31.8%
7D
0.2%

Author's Valuation

US$43.3

17.0% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on07 May 25
Fair value Decreased 20%

Shared on30 Apr 25
Fair value Increased 0.74%

AnalystConsensusTarget has increased profit margin from 29.9% to 51.0% and decreased future PE multiple from 26.2x to 15.2x.

Shared on23 Apr 25
Fair value Decreased 1.46%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on16 Apr 25
Fair value Decreased 2.16%

AnalystConsensusTarget has decreased revenue growth from 12.5% to 10.8%.

Shared on09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 2.85%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on10 Mar 25
Fair value Increased 30%

AnalystConsensusTarget has increased revenue growth from 7.2% to 12.5%, decreased profit margin from 36.7% to 28.6% and increased future PE multiple from 21.5x to 27.2x.